search
Back to results

Aspirin/Folate Prevention of Large Bowel Polyps

Primary Purpose

Colorectal Cancer, Polyps, Adenomas

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Aspirin
Folate
Sponsored by
Dartmouth-Hitchcock Medical Center
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for Colorectal Cancer focused on measuring Colorectal neoplasms, Adenomatous polyps

Eligibility Criteria

21 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: One neoplastic polyp removed within three months of study entry or within 16 months of study entry if over 1 cm in size or if subject has had a lifetime history of at least two polyps, with the entire large bowel seen by colonoscopy to be free of further polyps within 3 months of entry. An ability and willingness to follow the study protocol, as indicated by the subject's giving informed consent to participate. Good general health, with no severely debilitating diseases or active malignancy that might compromise the patient's ability to complete the study. Anticipated colonoscopic follow-up three years after the qualifying colonoscopy. Age between 21 and 80 years at the time of the intake colonoscopy. For women of childbearing potential, agreement to use effective birth control for the duration of the study. Intent not to take aspirin or aspirin-containing products, NSAIDs or folic acid for the length of the study unless required by a physician. Not randomized previously or currently in a chemoprevention trial, except for the: "Nutritional Prevention of Large Bowel Polyps" Study (Polyps Prevention Study I); and brief participation in the "VA Cooperative Study" with no continuing involvement. Exclusion Criteria: Invasive carcinoma in any colonic polyp removed. Familial colonic polyposis syndromes. Ulcerative colitis or Crohn's disease. Malabsorption syndrome (e.g. pancreatic insufficiency). Large bowel resection for any reason. Diagnosed narcotic or alcohol dependence Contraindication to aspirin use, including: documented peptic ulcer disease in the past 20 years aspirin sensitivity bleeding diathesis, including hemorrhagic stroke Likelihood of NSAID use recurring arthritis or other musculo-skeletal problems frequent NSAID use in 5 years preceding history of stroke or TIAs history of angina or myocardial infarction desire to take aspirin for the prevention of cardiovascular disease Required or contraindicated folic acid use pernicious anemia or folic acid deficiency Pregnancy or lactation.

Sites / Locations

  • USC/Kaiser
  • University of Colorado
  • University of Iowa
  • Henry Ford Health Sciences Center
  • University of Minnesota
  • Dartmouth Hitchcock Medical Center
  • University of North Carolina
  • Cleveland Clinic Foundation
  • University of Toronto

Outcomes

Primary Outcome Measures

1 or more adenomas
colorectal adenomas detected at follow-up colonoscopy

Secondary Outcome Measures

number of adenomas
colorectal adenomas detected at follow-up colonoscopy
1 or more advanced lesions
adenomas measuring at least 1 cm in diameter or with tubulovillous or villous features, severe dysplasia, or invasive cancer

Full Information

First Posted
January 3, 2006
Last Updated
March 11, 2020
Sponsor
Dartmouth-Hitchcock Medical Center
Collaborators
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00272324
Brief Title
Aspirin/Folate Prevention of Large Bowel Polyps
Official Title
Aspirin/Folate Prevention of Large Bowel Polyps
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
February 1992 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
January 2007 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Dartmouth-Hitchcock Medical Center
Collaborators
National Cancer Institute (NCI)

4. Oversight

5. Study Description

Brief Summary
This is a randomized controlled trial of aspirin and/or folate supplementation for the prevention of the recurrence of neoplastic polyps (adenomas) of the large bowel.
Detailed Description
This is a randomized controlled trial of aspirin and/or folate supplementation for the prevention of the recurrence of neoplastic polyps (adenomas) of the large bowel among subjects with a recent history of these tumors. The study is a randomized, double-blind, placebo-controlled trial with a 2 x 3 factorial design.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Cancer, Polyps, Adenomas
Keywords
Colorectal neoplasms, Adenomatous polyps

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2, Phase 3
Interventional Study Model
Factorial Assignment
Masking
Double
Allocation
Randomized
Enrollment
1121 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Aspirin
Intervention Type
Drug
Intervention Name(s)
Folate
Primary Outcome Measure Information:
Title
1 or more adenomas
Description
colorectal adenomas detected at follow-up colonoscopy
Time Frame
For aspirin: follow-up years 1-3; For folate: follow-up years 1-3 and years 4-8
Secondary Outcome Measure Information:
Title
number of adenomas
Description
colorectal adenomas detected at follow-up colonoscopy
Time Frame
For aspirin: follow-up years 1-3; For folate: follow-up years 1-3 and years 4-8
Title
1 or more advanced lesions
Description
adenomas measuring at least 1 cm in diameter or with tubulovillous or villous features, severe dysplasia, or invasive cancer
Time Frame
For aspirin: follow-up years 1-3; For folate: follow-up years 1-3 and years 4-8

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: One neoplastic polyp removed within three months of study entry or within 16 months of study entry if over 1 cm in size or if subject has had a lifetime history of at least two polyps, with the entire large bowel seen by colonoscopy to be free of further polyps within 3 months of entry. An ability and willingness to follow the study protocol, as indicated by the subject's giving informed consent to participate. Good general health, with no severely debilitating diseases or active malignancy that might compromise the patient's ability to complete the study. Anticipated colonoscopic follow-up three years after the qualifying colonoscopy. Age between 21 and 80 years at the time of the intake colonoscopy. For women of childbearing potential, agreement to use effective birth control for the duration of the study. Intent not to take aspirin or aspirin-containing products, NSAIDs or folic acid for the length of the study unless required by a physician. Not randomized previously or currently in a chemoprevention trial, except for the: "Nutritional Prevention of Large Bowel Polyps" Study (Polyps Prevention Study I); and brief participation in the "VA Cooperative Study" with no continuing involvement. Exclusion Criteria: Invasive carcinoma in any colonic polyp removed. Familial colonic polyposis syndromes. Ulcerative colitis or Crohn's disease. Malabsorption syndrome (e.g. pancreatic insufficiency). Large bowel resection for any reason. Diagnosed narcotic or alcohol dependence Contraindication to aspirin use, including: documented peptic ulcer disease in the past 20 years aspirin sensitivity bleeding diathesis, including hemorrhagic stroke Likelihood of NSAID use recurring arthritis or other musculo-skeletal problems frequent NSAID use in 5 years preceding history of stroke or TIAs history of angina or myocardial infarction desire to take aspirin for the prevention of cardiovascular disease Required or contraindicated folic acid use pernicious anemia or folic acid deficiency Pregnancy or lactation.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John A Baron, MD, MSc
Organizational Affiliation
Dartmouth-Hitchcock Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
USC/Kaiser
City
Los Angeles
State/Province
California
Country
United States
Facility Name
University of Colorado
City
Denver
State/Province
Colorado
Country
United States
Facility Name
University of Iowa
City
Iowa City
State/Province
Iowa
Country
United States
Facility Name
Henry Ford Health Sciences Center
City
Detroit
State/Province
Michigan
Country
United States
Facility Name
University of Minnesota
City
Minneapolis
State/Province
Minnesota
Country
United States
Facility Name
Dartmouth Hitchcock Medical Center
City
Lebanon
State/Province
New Hampshire
ZIP/Postal Code
03766
Country
United States
Facility Name
University of North Carolina
City
Chapel Hill
State/Province
North Carolina
Country
United States
Facility Name
Cleveland Clinic Foundation
City
Cleveland
State/Province
Ohio
Country
United States
Facility Name
University of Toronto
City
Toronto
State/Province
Ontario
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
12621133
Citation
Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003 Mar 6;348(10):891-9. doi: 10.1056/NEJMoa021735.
Results Reference
result
PubMed Identifier
34762658
Citation
Figueiredo JC, Passarelli MN, Wei W, Ahnen DJ, Morris JS, Corley L, Mehta T, Bartley AN, McKeown-Eyssen G, Bresalier RS, Barry EL, Goel A, Hernandez Mesa G, Hamilton SR, Baron JA. Proliferation, apoptosis and their regulatory protein expression in colorectal adenomas and serrated lesions. PLoS One. 2021 Nov 11;16(11):e0258878. doi: 10.1371/journal.pone.0258878. eCollection 2021.
Results Reference
derived
PubMed Identifier
34289971
Citation
Passarelli MN, Mott LA, Barry EL, Rees JR, Baron JA. Oral Antibiotics and Risk of New Colorectal Adenomas During Surveillance Follow-up. Cancer Epidemiol Biomarkers Prev. 2021 Oct;30(10):1974-1976. doi: 10.1158/1055-9965.EPI-21-0323. Epub 2021 Jul 21.
Results Reference
derived
PubMed Identifier
31401653
Citation
Passarelli MN, Barry EL, Rees JR, Mott LA, Zhang D, Ahnen DJ, Bresalier RS, Haile RW, McKeown-Eyssen G, Snover DC, Cole BF, Baron JA. Folic acid supplementation and risk of colorectal neoplasia during long-term follow-up of a randomized clinical trial. Am J Clin Nutr. 2019 Oct 1;110(4):903-911. doi: 10.1093/ajcn/nqz160.
Results Reference
derived
PubMed Identifier
31263057
Citation
Passarelli MN, Barry EL, Rees JR, Mott LA, Ahnen DJ, Baron JA. Body Composition and Aspirin Dose for Colorectal Adenoma Prevention in a Randomized Clinical Trial. Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1262-1265. doi: 10.1158/1055-9965.EPI-19-0205.
Results Reference
derived
PubMed Identifier
28218420
Citation
Fedirko V, McKeown-Eyssen G, Serhan CN, Barry EL, Sandler RS, Figueiredo JC, Ahnen DJ, Bresalier RS, Robertson DJ, Anderson CW, Baron JA. Plasma lipoxin A4 and resolvin D1 are not associated with reduced adenoma risk in a randomized trial of aspirin to prevent colon adenomas. Mol Carcinog. 2017 Aug;56(8):1977-1983. doi: 10.1002/mc.22629. Epub 2017 Mar 6.
Results Reference
derived
PubMed Identifier
27094489
Citation
Yip WK, Bonetti M, Cole BF, Barcella W, Wang XV, Lazar A, Gelber RD. Subpopulation Treatment Effect Pattern Plot (STEPP) analysis for continuous, binary, and count outcomes. Clin Trials. 2016 Aug;13(4):382-90. doi: 10.1177/1740774516643297. Epub 2016 Apr 19.
Results Reference
derived
PubMed Identifier
19923375
Citation
Hazra A, Selhub J, Chao WH, Ueland PM, Hunter DJ, Baron JA. Uracil misincorporation into DNA and folic acid supplementation. Am J Clin Nutr. 2010 Jan;91(1):160-5. doi: 10.3945/ajcn.2009.28527. Epub 2009 Nov 18.
Results Reference
derived
PubMed Identifier
17551129
Citation
Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, McKeown-Eyssen G, Summers RW, Rothstein RI, Burke CA, Snover DC, Church TR, Allen JI, Robertson DJ, Beck GJ, Bond JH, Byers T, Mandel JS, Mott LA, Pearson LH, Barry EL, Rees JR, Marcon N, Saibil F, Ueland PM, Greenberg ER; Polyp Prevention Study Group. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA. 2007 Jun 6;297(21):2351-9. doi: 10.1001/jama.297.21.2351.
Results Reference
derived

Learn more about this trial

Aspirin/Folate Prevention of Large Bowel Polyps

We'll reach out to this number within 24 hrs